See more : National CineMedia, Inc. (NCMI) Income Statement Analysis – Financial Results
Complete financial analysis of Ceapro Inc. (CRPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ceapro Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Theta Gold Mines Limited (TGM.AX) Income Statement Analysis – Financial Results
- Arizona Silver Exploration Inc. (AZS.V) Income Statement Analysis – Financial Results
- NVR, Inc. (NVR) Income Statement Analysis – Financial Results
- International Network System Public Company Limited (ITNS.BK) Income Statement Analysis – Financial Results
- SkyCity Entertainment Group Limited (SKC.NZ) Income Statement Analysis – Financial Results
Ceapro Inc. (CRPOF)
About Ceapro Inc.
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. It operates in two segments, Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment develops proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients sold directly to the end-user primarily through online website sales and through select natural products stores. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.63M | 18.84M | 17.20M | 15.12M | 12.88M | 11.59M | 12.93M | 13.67M | 10.67M | 8.89M | 6.52M | 5.17M | 5.79M | 5.58M | 4.37M | 4.23M | 3.45M | 3.31M | 2.68M | 1.96M | 2.22M | 1.51M | 1.15M | 808.85K | 300.00K | 400.00K | 2.30M | 600.00K |
| Cost of Revenue | 6.07M | 7.82M | 7.51M | 7.50M | 7.43M | 5.45M | 5.65M | 4.32M | 3.64M | 4.13M | 3.43M | 2.72M | 2.54M | 3.04M | 2.25M | 2.64M | 1.79M | 1.73M | 1.12M | 1.02M | 928.12K | 754.13K | 728.41K | 517.68K | 200.00K | 100.00K | 1.90M | 500.00K |
| Gross Profit | 3.56M | 11.02M | 9.69M | 7.62M | 5.45M | 6.14M | 7.27M | 9.35M | 7.03M | 4.76M | 3.10M | 2.45M | 3.25M | 2.54M | 2.12M | 1.59M | 1.65M | 1.58M | 1.56M | 934.13K | 1.29M | 757.38K | 421.03K | 291.17K | 100.00K | 300.00K | 400.00K | 100.00K |
| Gross Profit Ratio | 36.99% | 58.48% | 56.35% | 50.41% | 42.28% | 52.95% | 56.26% | 68.40% | 65.89% | 53.58% | 47.50% | 47.41% | 56.13% | 45.46% | 48.47% | 37.53% | 47.97% | 47.70% | 58.13% | 47.73% | 58.16% | 50.11% | 36.63% | 36.00% | 33.33% | 75.00% | 17.39% | 16.67% |
| Research & Development | 2.75M | 1.79M | 3.78M | 1.88M | 2.39M | 2.67M | 1.61M | 919.12K | 625.21K | 578.36K | 731.17K | 856.19K | 996.72K | 774.06K | 0.00 | 0.00 | 695.66K | 365.42K | 162.83K | 302.49K | 353.74K | 259.06K | 397.00K | 293.43K | 400.00K | 800.00K | 2.30M | 100.00K |
| General & Administrative | 7.42M | 3.70M | 3.24M | 3.28M | 2.95M | 3.00M | 2.84M | 2.19M | 2.52M | 1.98M | 1.71M | 1.80M | 1.37M | 1.30M | 1.68M | 1.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.48K | 29.56K | 47.12K | 111.04K | 425.23K | 225.55K | 32.11K | 4.33K | 7.62K | 13.70K | 84.90K | 198.65K | 111.36K | 69.51K | 183.69K | 385.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.07M | 3.73M | 3.29M | 3.39M | 3.38M | 3.23M | 2.87M | 2.19M | 2.53M | 2.00M | 1.79M | 1.99M | 1.49M | 1.37M | 1.86M | 2.07M | 1.68M | 1.36M | 1.24M | 963.92K | 1.27M | 814.11K | 691.92K | 777.79K | 800.00K | 1.10M | 3.70M | 1.80M |
| Other Expenses | 129.31K | 181.46K | 273.12K | -93.71K | -353.32K | -1.12M | -738.09K | -629.30K | 0.00 | 0.00 | 0.00 | 0.00 | -7.34K | -479.44K | -219.38K | -2.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.82M | 5.52M | 7.07M | 5.28M | 5.77M | 5.17M | 6.63M | 3.11M | 3.15M | 2.58M | 2.53M | 2.85M | 2.48M | 1.43M | 1.90M | 2.81M | 2.17M | 1.87M | 1.56M | 1.36M | 1.68M | 1.10M | 1.11M | 1.10M | 1.20M | 2.00M | 8.20M | 2.20M |
| Cost & Expenses | 15.89M | 13.34M | 14.57M | 12.77M | 13.21M | 10.62M | 12.29M | 7.43M | 6.79M | 6.70M | 5.95M | 5.57M | 5.02M | 4.47M | 4.16M | 5.45M | 3.96M | 3.61M | 2.69M | 2.38M | 2.61M | 1.85M | 1.84M | 1.62M | 1.40M | 2.10M | 10.10M | 2.70M |
| Interest Income | 436.22K | 93.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K |
| Interest Expense | 128.13K | 129.97K | 151.89K | 175.16K | 201.50K | 48.05K | 20.03K | 37.59K | 52.78K | 63.51K | 126.66K | 112.90K | 180.81K | 110.90K | 77.03K | 83.65K | 43.83K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | 0.00 | 100.00K | 0.00 | 100.00K |
| Depreciation & Amortization | 1.95M | 1.91M | 1.88M | 1.84M | 1.83M | 578.60K | 326.10K | 359.45K | 392.32K | 296.38K | 292.64K | 292.53K | 297.28K | 290.64K | 356.96K | 336.57K | 120.44K | 146.78K | 161.55K | 91.96K | 59.96K | 23.57K | 24.25K | 27.99K | 0.00 | 100.00K | 2.20M | 300.00K |
| EBITDA | -4.31M | 7.54M | 4.72M | 4.04M | 1.10M | 371.48K | 110.92K | 6.40M | 4.08M | 2.36M | 866.33K | -109.12K | 1.06M | 1.41M | 571.46K | -889.10K | -393.57K | -148.94K | 158.33K | -332.28K | -330.37K | -315.78K | -667.88K | -780.05K | -1.10M | -1.60M | -5.60M | -1.80M |
| EBITDA Ratio | -44.73% | 40.00% | 27.46% | 26.71% | 8.52% | 3.20% | 0.86% | 46.78% | 38.20% | 26.54% | 13.28% | -2.11% | 18.37% | 25.22% | 13.08% | -21.03% | -11.42% | -4.50% | 5.90% | -16.98% | -14.89% | -20.89% | -58.10% | -96.44% | -366.67% | -400.00% | -243.48% | -300.00% |
| Operating Income | -6.26M | 5.31M | 2.42M | 2.12M | -586.66K | 128.08K | 2.66M | 6.00M | 3.63M | 2.00M | 447.03K | -514.55K | 584.91K | 992.80K | 137.47K | -1.31M | -514.01K | 21.64K | -3.22K | -424.24K | -390.33K | -339.35K | -692.14K | -808.04K | -1.10M | -1.70M | -7.80M | -2.10M |
| Operating Income Ratio | -64.93% | 28.21% | 14.05% | 13.99% | -4.55% | 1.10% | 20.55% | 43.87% | 34.03% | 22.49% | 6.85% | -9.96% | 10.11% | 17.80% | 3.15% | -30.97% | -14.91% | 0.65% | -0.12% | -21.68% | -17.60% | -22.45% | -60.21% | -99.90% | -366.67% | -425.00% | -339.13% | -350.00% |
| Total Other Income/Expenses | 350.72K | 277.94K | -4.61K | -490.51K | -810.06K | -1.05M | -1.07M | -878.91K | -658.56K | -596.51K | -401.99K | -23.81K | -7.34K | 310.10K | -219.38K | -2.29M | -875.32K | -294.00K | -53.79K | 26.51K | 553.01K | 462.33K | 459.25K | -12.92K | 100.00K | -12.50M | -11.00M | -1.40M |
| Income Before Tax | -5.90M | 5.78M | 2.62M | 1.86M | -1.14M | -921.23K | -426.82K | 5.36M | 3.83M | 1.59M | 175.81K | -538.35K | 577.57K | 501.08K | -81.90K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -232.88K | -820.96K | -1.00M | -14.20M | -18.80M | -3.50M |
| Income Before Tax Ratio | -61.29% | 30.66% | 15.23% | 12.27% | -8.82% | -7.95% | -3.30% | 39.22% | 35.94% | 17.93% | 2.69% | -10.42% | 9.98% | 8.99% | -1.87% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -20.26% | -101.50% | -333.33% | -3,550.00% | -817.39% | -583.33% |
| Income Tax Expense | -1.19M | 1.38M | -223.69K | 81.45K | -3.41K | -605.69K | 531.46K | 1.74M | -1.09M | 63.51K | 126.66K | 112.90K | 180.81K | 123.18K | 64.48K | 83.65K | 369.93K | 46.35K | 51.70K | 28.50K | 47.77K | 93.56K | 113.22K | 94.93K | -100.00K | 100.00K | 1.00M | 200.00K |
| Net Income | -4.71M | 4.40M | 3.37M | 1.86M | -1.13M | -315.54K | -958.28K | 3.62M | 4.92M | 1.59M | 175.81K | -538.35K | 577.57K | 463.72K | -69.35K | -3.60M | -1.39M | -272.36K | -57.01K | -397.74K | 442.04K | 115.77K | -346.10K | -915.90K | -900.00K | -14.30M | -19.80M | -3.70M |
| Net Income Ratio | -48.89% | 23.34% | 19.57% | 12.27% | -8.79% | -2.72% | -7.41% | 26.47% | 46.14% | 17.93% | 2.69% | -10.42% | 9.98% | 8.32% | -1.59% | -85.13% | -40.30% | -8.23% | -2.12% | -20.32% | 19.93% | 7.66% | -30.11% | -113.23% | -300.00% | -3,575.00% | -860.87% | -616.67% |
| EPS | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| EPS Diluted | -0.06 | 0.06 | 0.04 | 0.02 | -0.01 | 0.00 | -0.01 | 0.05 | 0.08 | 0.03 | 0.00 | -0.01 | 0.01 | 0.01 | 0.00 | -0.08 | -0.03 | -0.01 | 0.00 | -0.01 | 0.01 | 0.00 | -0.01 | -0.04 | -0.04 | -0.79 | -1.27 | -0.20 |
| Weighted Avg Shares Out | 78.27M | 77.96M | 77.67M | 77.59M | 77.19M | 76.20M | 75.34M | 67.68M | 61.80M | 60.90M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 31.57M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
| Weighted Avg Shares Out (Dil) | 78.27M | 78.58M | 78.59M | 78.14M | 77.19M | 76.20M | 75.34M | 71.33M | 65.20M | 62.53M | 60.28M | 60.28M | 56.56M | 53.22M | 49.58M | 47.05M | 42.34M | 37.19M | 36.34M | 39.77M | 34.00M | 28.94M | 29.36M | 21.23M | 22.50M | 18.10M | 15.59M | 18.50M |
Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to Shareholders
MILWAUKEE , June 7, 2024 /PRNewswire/ -- Ademi LLP is investigating Aeterna (Nasdaq: AEZS) for possible breaches of fiduciary duty and other violations of law in its transaction with Ceapro. Click here to learn how to join our investigation: https://www.ademilaw.com/case/aeterna-zentaris-inc or...
Aeterna Zentaris and Ceapro Complete Merger Transaction
TORONTO and EDMONTON, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful completion...
Aeterna Zentaris and Ceapro Complete Merger Transaction
TORONTO and EDMONTON, Alberta, June 03, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) and Ceapro Inc. (TSX-V: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce the successful...
Ceapro Inc. Reports Financial Results for First Quarter 2024 and Provides Corporate Update
– Q1 2024 marked by significant advancement of R&D projects focused on avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “Transaction”) with Ceapro Inc. (“Ceapro”).
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights
– 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock...
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
TORONTO and EDMONTON, Alberta, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative biopharmaceutical development companies, are pleased to announce today that leading independent...
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
Source: https://incomestatements.info
Category: Stock Reports